Paratus Sciences Paratus is decoding evolution to discover and develop first-in-class medicines for serious diseases where today’s therapies fall short. We integrate evolutionary biology, AI-powered discovery and deep multi-omic data to uncover biologically validated pathways that can inform new medicines. We are advancing PS-1001, a first-in-class pan-inflammasome inhibitor and our lead program, toward first-in-human studies, alongside a broader pipeline of differentiated therapeutic programs in cardiometabolic and immune and inflammatory diseases. We're headquartered in Boston, Mass., with research operations in Singapore.